Skip to content

The Effect of Radiofrequency of 448 kHz on Pain and Function

The Effect of Capacitive and Resistive Monopolar Radiofrequency of 448 kHz on Pain and Function in People Diagnosed With Lumbar Pain Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05682287
Enrollment
62
Registered
2023-01-12
Start date
2022-03-01
Completion date
2022-07-01
Last updated
2023-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low-back Pain, Low Back Pain, Recurrent, Lumbago

Keywords

chronic low back pain, 448kHz capacitive resistive monopolar radiofrequency, randomised controlled trial, pain, disability

Brief summary

The goal of this trial is to compare the effects 448kHz capacitive resistive monopolar radiofrequency (CRM) with Proprioceptive Neuromuscular Facilitation (PNF) versus only PNF in chronic low back pain patients. The main questions it aims to answer are: 1. Is there any difference in interventions on reduction of pain. 2. Is there any difference in interventions on reduction of disability. Participants will in the experimental group will be treated with a combination of: 1. 448kHz capacitive resistive monopolar radiofrequency and, 2. PNF intervention Participants will in the control group will be treated only using 1\. PNF intervention (identical to experimental group) Researchers will compare experimental and control group to see if there are differences in reduction of pain and disability.

Interventions

DEVICE448kHz capacitive resistive monopolar radiofrequency

Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.

OTHERProprioceptive Neuromuscular Facilitation

Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.

Sponsors

University of Applied Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* older than 18 years, chronic low back pain (CLBP)

Exclusion criteria

* spinal fractures, radiculopathies, history of spinal surgery, spinal stenosis, history of thrombosis, pacemaker, pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline: Pain - Visual Analogue Scale (VAS)Change from baseline pain after two weeks (14 days).Change from baseline pain, measured by 0-10 Visual Analogue Scale (VAS). VAS has a minimum score of 0 and a maximum score of 10. Higher score indicates a worse outcome (e.g., greater pain intensity).
Change from baseline: Disability - ODI (Oswestry Low Back Pain Disability Questionnaire)Change from baseline disability after two weeks (14 days).Change from baseline disability, measured by Oswestry Low Back Pain Disability Questionnaire. ODI has a minimum score of 0% and maximum score of 100%. Higher score indicates a worse outcome (e.g., greater disability).

Secondary

MeasureTime frameDescription
Change from baseline: Disability - Quebec Back Pain Disability Scale (QBPD)Change from baseline disability after two weeks (14 days).Change from baseline disability, measured by Quebec Back Pain Disability Scale. QBPD has a minimum score of 20 and maximum score of 100. Higher score indicates a worse outcome (e.g., greater disability).
Change from baseline: Roland-Morris Disability Questionnaire (RMDQ)Change from baseline disability after two weeks (14 days).Change from baseline disability, measured by Roland-Morris Disability Questionnaire. RMDQ has a minimum score of 0 and maximum score of 24. Higher score indicates a worse outcome (e.g., greater pain-related disability).

Countries

Croatia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026